Skip to main content
Premium Trial:

Request an Annual Quote

Argonne's IGSB to Use 454, Illumina Sequencers for Microbial Research

NEW YORK (GenomeWeb News) - The Institute for Genomics and Systems Biology, a joint venture of the Department of Energy's Argonne National Laboratory and the University of Chicago, said today that it has acquired two second-generation sequencers: a Roche/454 FLX and an Illumina Genome Analyzer.
IGSB said in a statement that the 454 FLX is “ideally suited for studying microbial communities by de novo sequencing” because it provides 400,000 DNA fragments with a read length of around 250 base pairs, which represents "either a significant part of the genome of a single organism or a random snapshot of parts of multiple genomes.”
The institute said it plans to use the Illumina sequencer for resequencing projects because it provides “more but shorter reads” than the FLX.
IGSB said it acquired the instruments primarily to support three research projects at Argonne: a study of carbon dioxide sequestration in soil on the microbial level; a metagenomics study of the microbial population in chronoseries plots at DOE's Fermi National Accelerator Laboratory; and another metagenomics study of the role of microbial communities in subsurface remediation of inorganic contaminates.
The systems will also be available to other Argonne and University of Chicago researchers who require DNA sequencing. IGSB said it also intends to make the instruments available to “select peer-reviewed proposals" from researchers from other organizations in the near future.

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.